Evidence map›Paper›PMID 37421288›Full record

ArticleJournal of the American Heart Association2023

Myocardial Infarction Across COVID-19 Pandemic Phases: Insights From the Veterans Health Affairs System.

Celina M Yong, Laura Graham, Tariku J Beyene, Shirin Sadri, Juliette Hong, Tom Burdon, William F Fearon, Steven M Asch, Mintu Turakhia, Paul Heidenreich

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Celina M YongVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.ORCID 0000-0003-3054-6576
Laura GrahamHealth Economics Resource Center (HERC), VA Palo Alto Healthcare System Palo Alto CA USA.ORCID 0000-0002-7327-3793
Tariku J BeyeneVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.ORCID 0000-0002-7474-1966
Shirin SadriDepartment of Medicine Stanford School of Medicine Stanford CA USA.
Juliette HongVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.
Tom BurdonVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.
William F FearonVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.ORCID 0000-0003-1799-1368
Steven M AschVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.
Mintu TurakhiaVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.ORCID 0000-0001-8025-0904
Paul HeidenreichVeterans Affairs Palo Alto Healthcare System Palo Alto CA USA.ORCID 0000-0001-7730-8490
VA Palo Alto Health Care System · USStanford Medicine · US

Funding

HSRD VA IK2 HX002236
6 · The paper itself

Abstract

Background Cardiovascular procedural treatments were deferred at scale during the COVID-19 pandemic, with unclear impact on patients presenting with non-ST-segment-elevation myocardial infarction (NSTEMI). Methods and Results In a retrospective cohort study of all patients diagnosed with NSTEMI in the US Veterans Affairs Healthcare System from January 1, 2019 to October 30, 2022 (n=67 125), procedural treatments and outcomes were compared between the prepandemic period and 6 unique pandemic phases: (1) acute phase, (2) community spread, (3) first peak, (4) post vaccine, (5) second peak, and (6) recovery. Multivariable regression analysis was performed to assess the association between pandemic phases and 30-day mortality. NSTEMI volumes dropped significantly with the pandemic onset (62.7% of prepandemic peak) and did not revert to prepandemic levels in subsequent phases, even after vaccine availability. Percutaneous coronary intervention and coronary artery bypass grafting volumes declined proportionally. Compared with the prepandemic period, patients with NSTEMI experienced higher 30-day mortality during Phases 2 and 3, even after adjustment for COVID-19-positive status, demographics, baseline comorbidities, and receipt of procedural treatment (adjusted odds ratio for Phases 2 and 3 combined, 1.26 [95% CI, 1.13-1.43],

Indexed as

COVID-19Myocardial InfarctionNon-ST Elevated Myocardial InfarctionPercutaneous Coronary InterventionST Elevation Myocardial InfarctionHumansPandemicsRetrospective StudiesTreatment OutcomeVeterans Healthacute coronary syndromeacute myocardial infarctionCOVID‐19non–ST‐segment–elevation myocardial infarction

Identifiers

PMID37421288
PMCPMC10382121
OpenAlexW4383621200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.